Vasala Kaija, Pääkkö Paavo, Turpeenniemi-Hujanen Taina
Department of Oncology and Radiotherapy, Oulu University Hospital and University of Oulu, Oulu, Finland.
Urology. 2003 Nov;62(5):952-7. doi: 10.1016/s0090-4295(03)00660-5.
To analyze the expression of matrix metalloproteinase-2 (MMP-2) in bladder cancer specimens and evaluate its value as a prognostic biomarker. MMPs, particularly MMP-2, play an important role in tumor cell invasion and metastasis in several human cancers.
The MMP-2 protein was assayed semiquantitatively in 54 primary bladder carcinomas of varying grade and stage. A specific monoclonal antibody for MMP-2 was used to detect the antigen by a semiquantitative immunohistochemical staining of paraffin-embedded tissue sections.
Of the 54 specimens, 35 (65%) overexpressed MMP-2 protein when stained sections were scored independently by three observers. A consensus score was established before clinical data analysis. The 5-year disease-specific survival was significantly (P = 0.0335) lower in the MMP-2 positive cases (n = 35) than in the MMP-2 negative cases (n = 19), 53% versus 77%. The 5 and 10-year relapse-free survival rate was 32% and 24% in the MMP-2 positive patients, respectively, compared with 68% for the MMP-2 negative patients (P = 0.0718). MMP-2 overexpression correlated with bladder cancer stage but not with grade, partly contrary to previous observations.
The results of this study demonstrated that MMP-2 protein overexpression may be an independent prognostic biomarker for bladder cancer progression.
分析基质金属蛋白酶-2（MMP-2）在膀胱癌标本中的表达，并评估其作为预后生物标志物的价值。基质金属蛋白酶，尤其是MMP-2，在几种人类癌症的肿瘤细胞侵袭和转移中起重要作用。
对54例不同分级和分期的原发性膀胱癌进行MMP-2蛋白的半定量检测。使用针对MMP-2的特异性单克隆抗体，通过对石蜡包埋组织切片进行半定量免疫组织化学染色来检测抗原。
在54个标本中，当由三名观察者独立对染色切片评分时，35个（65%）标本MMP-2蛋白过表达。在临床数据分析之前建立了共识评分。MMP-2阳性病例（n = 35）的5年疾病特异性生存率显著低于MMP-2阴性病例（n = 19）（P = 0.0335），分别为53%和77%。MMP-2阳性患者的5年和10年无复发生存率分别为32%和24%，而MMP-2阴性患者为68%（P = 0.0718）。MMP-2过表达与膀胱癌分期相关，但与分级无关，这部分与先前的观察结果相反。
本研究结果表明，MMP-2蛋白过表达可能是膀胱癌进展的独立预后生物标志物。
